Marshall Wace
MXCT icon

Marshall Wace’s MaxCyte MXCT Stock Holding History

Marshall Wace’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25M Buy
1,014,778
+915,866
+926% +$913K ﹤0.01% 2089
2026
Q1 		$69.2K Buy
+98,912
New +$92.3K ﹤0.01% 2943
2025
Q4 		– Sell
-12,354
Closed -$19.5K – 3292
2025
Q3 		$19.5K Sell
12,354
-116,954
-90% -$203K ﹤0.01% 2783
2025
Q2 		$282K Buy
+129,308
New +$313K ﹤0.01% 2346
2025
Q1 		– Sell
-252,333
Closed -$1.05M – 2929
2024
Q4 		$1.05M Buy
252,333
+29,739
+13% +$112K ﹤0.01% 1709
2024
Q3 		$866K Sell
222,594
-277,075
-55% -$1.17M ﹤0.01% 1705
2024
Q2 		$1.96M Buy
+499,669
New +$2.15M ﹤0.01% 1381
2022
Q3 		– Sell
-257,068
Closed -$1.22M – 3644
2022
Q2 		$1.22M Buy
+257,068
New +$1.27M ﹤0.01% 2324
2022
Q1 		– Sell
-986,437
Closed -$10.1M – 3771
2021
Q4 		$10.1M Buy
+986,437
New +$10.6M 0.02% 860

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Marshall Wace's MXCT Position: Q2 2026 in Review

Marshall Wace increased its MaxCyte (MXCT) stake by 926% in Q2 2026, buying an estimated $913K and bringing the position to 1,014,778 shares worth $1.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Marshall Wace first reported a position in MXCT in Q4 2021 and has held it in 9 quarters since. The position peaked at $10.1M in Q4 2021. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Marshall Wace held 1,014,778 shares of MaxCyte worth $1.25M as of Q2 2026.
  • Marshall Wace bought 915,866 MaxCyte shares in Q2 2026, an estimated $913K.
  • MaxCyte made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2089 holding.
  • Marshall Wace first reported a position in MaxCyte in Q4 2021 and has held it in 9 quarters since.
  • Marshall Wace's MaxCyte position peaked at $10.1M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.